ORIFARM A/S: Financial statements 2025
CVR: 26058708
Source: annual report 2025, Danish Business Authority
01/01/2025 – 31/12/2025
ORIFARM A/S (CVR 26058708) has filed annual accounts for 2025. In 2025, the company reported revenue of DKK 1,174,659,000 and a net result of DKK 9,727,000 compared with DKK 14,865,000 the year before. That is a decrease of 4% compared with the year before. The profit margin was 0.8%. Equity in the 2025 report amounted to DKK 44,048,000. The solvency ratio was 29.7%. The company had 37 employees in the financial year.
- Revenue
- DKK 1,174,659,000
- Gross Profit
- DKK 23,018,000
- Profit/Loss
- DKK 9,727,000
- Equity
- DKK 44,048,000
- Total Assets
- DKK 148,121,000
- Employees
- 37
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2025 | 1.2B | 23M | 9.7M | 44M | 37 |
| 2024 | 1.2B | 23.2M | 14.9M | 53.9M | 37 |
| 2023 | 1.6B | 27.6M | 18.9M | 76.3M | 37 |
| 2022 | 1.4B | 20.2M | 9.9M | 57.4M | 34 |
| 2021 | 1.5B | 19.5M | 8.2M | 47.4M | 40 |
Official annual report
How creditworthy is ORIFARM A/S?
See the CDS score and get a full credit report with recommended credit limit and payment terms.
Read about the CDS scoreEvents in 2025
ORIFARM A/S has won the tender "Amgros 2026 1.450.b" issued by Amgros I/S worth 72,960,000 DKK.
ORIFARM A/S has won the tender "Amgros 2026 1.1216.a" issued by Amgros I/S worth 19,794,473 DKK.
ORIFARM A/S has won the tender "Amgros 2026 1.209.a" issued by Amgros I/S worth 22,313,896 DKK.
ORIFARM A/S has won the tender "Amgros 2026 1.708.b" issued by Amgros I/S worth 321,891,182 DKK.
ORIFARM A/S has won the tender "Amgros 2026 1.710.a" issued by Amgros I/S worth 91,191,236 DKK.
ORIFARM A/S has won the tender "Amgros 2026 1.610.a" issued by Amgros I/S worth 75,600,000 DKK.
ORIFARM A/S has won the tender "Amgros 2026 1.1201.a" issued by Amgros I/S worth 358,514,920 DKK.
ORIFARM A/S has won the tender "Amgros 2026 2.1301.a" issued by Amgros I/S worth 39,781,779 DKK.
ORIFARM A/S has won the tender "Amgros 2026 2.1303.b" issued by Amgros I/S worth 4,100,779 DKK.
ORIFARM A/S has won the tender "Amgros 2026 2.1302.b" issued by Amgros I/S worth 161,990,275 DKK.
About ORIFARM A/S
ORIFARM A/S is a Danish company of the type Aktieselskab based in Odense S, founded in 2001. The company is registered under the industry Engroshandel med medicinalvarer og sygeplejeartikler. The company was previously named JUT NR. 2181 A/S. The management consists of Thomas Brandhof. The board consists of Hans Carl Bøgh-Sørensen (chair), Mads Fink Eriksen and Nicki Lund Kristensen. The company is owned by ORIFARM PI A/S. The company has 39 employees (2026). In 2025, the company reported revenue of DKK 1,174,659,000 and a net result of DKK 9,727,000 compared with DKK 14,865,000 the year before. Equity in the 2025 report amounted to DKK 44,048,000.